Clinical Trial Update: BLeeding Events and Maintenance DoSe of PraSugrel [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the maintenance dosing of prasugrel reported bleeding events. The study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• EFFIENT (prasugrel hydrochloride)

Snippet

Sponsor: David Antoniucci | Conditions: Adverse Reaction to Antiplatelet Agent, Acute Coronary Syndrome | Phase 4 | Status: TERMINATED